Other News

MedRhythms’ InTandem® Rehabilitation System for Chronic Stroke Gait Impairment Receives Final Medicare Payment Determination from CMS

The pricing determination for HCPCS code E3200 will take effect on April 1, 2025 PORTLAND, Maine, Jan. 16, 2025 /PRNewswire/ — MedRhythms, Inc. today announced that InTandem®, the company’s flagship rehabilitation system for chronic stroke gait impairment, received a final pricing…

Venova Medical Announces First Subjects Enrolled in VENOS-2 IDE Study of the Velocity Percutaneous AVF System

The VENOS-2 prospective, multicenter study is being performed under an Investigational Device Exemption (IDE) granted by the FDA and will evaluate the feasibility of the company’s Velocity pAVF System which is designed to enable a minimally invasive approach for the creation of an AV fistula for hemodialysis vascular access. LOS […]

CardioFocus Announces Publication of 1-Year ECLIPSE AF Clinical Trial Results

MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the publication of the 12-month results from the ECLIPSE AF trial in Circulation: Arrhythmia & Electrophysiology, demonstrating an overall 90.2% 12-month freedom from clinically significant atrial arrhythmia among paroxysmal atrial fibrillation (AF) patients undergoing […]

Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program

January 14, 2025 09:00 AM Eastern Standard Time AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also adds Omega Funds and includes participation […]

Radical Catheter Technologies’ 8F Neurovascular Catheter Receives US FDA 510(k) Clearance, Second for the Best-in-Class Ribbon Technology Platform

Company Announces New Headquarters, a State-of-the-Art Manufacturing Facility to Expand Commercialization of the Radical Neurovascular Catheter Portfolio to Include a Wide Range of Sizes and Indications Enhancing Efficiency and Precision in Neurosurgery Company Announces New Headquarters, a State-of-the-Art Manufacturing Facility to Expand Commercialization of the Radical Neurovascular Catheter Portfolio to Include a Wide Range of Sizes and Indications Enhancing Efficiency and Precision in Neurosurgery

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ — NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its…